The number of infused cells is a very important factor in cord blood transplant (CBT) engraftment. Prior ex vivo expansion of aliquots of transplanted cord blood (CB) units is being investigated as a procedure to increase engraftment potential, but results are difficult to evaluate due to a lack of markers for assessing the contribution of expanded cells. We transplanted five patients, infusing the best available CB unit and cells from a second donor simultaneously. In two patients, these cells were obtained from another frozen CB unit by CD34
Summary:
The number of infused cells is a very important factor in cord blood transplant (CBT) engraftment. Prior ex vivo expansion of aliquots of transplanted cord blood (CB) units is being investigated as a procedure to increase engraftment potential, but results are difficult to evaluate due to a lack of markers for assessing the contribution of expanded cells. We transplanted five patients, infusing the best available CB unit and cells from a second donor simultaneously. In two patients, these cells were obtained from another frozen CB unit by CD34
+ positive selection and culture expansion; the other three patients received uncultured highly purified haploidentical CD34
+ cells. The first two patients had DNA from the culture expanded CB cells detected only for a few days around day +11 when the absolute neutrophil count (ANC) was Ͻ200/l; thereafter and when the ANC was Ͼ500/l, only donor DNA from the uncultured CB was detected. For the other three patients, DNA analysis showed early and transient granulocyte engraftment of haploidentical cells, progressively replaced by the CB-derived granulocytes. We concluded that: (1) simultaneous infusion of lymphocyte-depleted HLA highly mismatched haematopoietic progenitor cells has not produced unfavourable effects for CBT; Cord blood (CB) is well established as a source of haematopoietic stem cells for allogeneic transplantation, with more than 2000 unrelated cord blood transplants (CBT) performed in the last 12 years. Although it has several advantages over bone marrow transplantation (BMT), for example, rapid availability, lower risk of transmission of viral disease, and less GVHD, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] several controversial issues still remain. While a number of adult transplants have been performed successfully, CBT has been used mostly for paediatric patients and analysis of clinical results has shown that the number of nucleated cells infused is the most important factor in predicting the outcome of the transplant. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] A matter of concern is whether the number of cells required for an adult transplant are present in a typical CB unit, which contains a limited number of nucleated cells that range from about 1.30 to more than 37 × 10 Several groups have evaluated CBT of units partially subjected to previous culture, trying to increase the number of haematopoietic progenitor cells and, thus, to enhance engraftment. [15] [16] [17] [18] The reported engraftment times, however, are similar to those of CBTs with units without any previous culture. [1] [2] [3] [4] [5] [6] 19 Unfortunately, due to a lack of genetic markers for differentiating between cells of different origin, it has not been possible to assess to what extent the expanded cells contributed to engraftment. Expanded cells might not engraft as well as non-cultured ones. We have recently shown, using xenogeneic transplant of human CB cells into SCID/NOD mice, that ex vivo expansion of haematopoietic CB progenitors may result in the loss of capacity for early engraftment. This could be attributed to reduced capacity for post-transplant homing and/or proliferative growth. 20 Similar and also contradictory observations have been made by others. 21, 22 Simultaneous transplantation of several unexpanded CB units has also been attempted to enhance engraftment. 23 We theorized that simultaneous transplantation of an unexpanded CB unit, together with one previously subjected to culture, could provide valuable information about the relative engraftment kinetics of cultured and uncultured CB cells in human recipients, since the two units could have differing genetic markers. 19 We also theorized that double transplants, employing non-expanded CB units and highly T cell-depleted uncultured haploidentical stem cells from a family donor, could result in an earlier increase of granulocytes that could provide antimicrobial protection during the longer engraftment period of the CB stem cells. These transplants would also provide comparative data to evaluate the engraftment kinetics of the culture-expanded CB cells in human recipients receiving double CBTs. This approach could have other unknown unfavourable or favourable effects. The former could include higher risks of GVHD, given the dual stem cell populations of different histocompatibility or lack of engraftment due to immunoreactivity among the transplanted units. Favourable effects could include induction of immunotolerance that could reduce risks of rejection and/or GVHD. 24 In the Hospital P de Hierro, Universidad Autónoma de Madrid, we have transplanted five refractory acute leukaemia patients with the best available CB units (in terms of both HLA compatibility and cell content) in conjunction with cells from a different donor. In two cases, these were obtained by culture expansion of all the CD34 + cells that were recovered from a different CB unit. For the other three, they were purified and uncultured PB CD34
+ cells obtained from a haploidentical sibling. In all cases, these cells were highly devoid of contaminating lymphocytes. Our primary objective has been to obtain shortened intervals to granulocyte recovery; a secondary objective has been to investigate both the engraftment potential of culture expanded CB cells and the engraftment kinetics of cotransplanted cells of different genetic origin.
Patients and methods

Patients
Pre-transplant clinical features of the patients are shown in Table 1 . All patients were adults aged between 25 to 47 years, weighing 66 to 92 kg, with a diagnosis of high risk acute leukaemia. Patients were in relatively good clinical condition despite their poor prognosis and did not have potential donors with acceptable HLA compatibility. All had positive CMV serology. 
Transplantation strategies
The double transplant strategies are outlined in a phase I-II protocol. This is offered to eligible patients as compassionate treatment with specific consent from the Hospital Ethical Committee for each individual case. Signed consent from each patient is obtained after providing appropriate information, according to national and international regulations for research on human subjects.
In patients Nos 1 and 2, the strategy was to successively infuse the best available CB unit immediately after thawing and the cells resulting from the ex vivo culture of all the CD34 + cells recovered from the second best available unit, with no more than four HLA-A, -B, -DR Ag differences. These CD34 + cells were obtained by positive immunomagnetic (Isolex 50; Baxter, Deerfield, IL, USA) selection and ex vivo static culture for 6 days in a serum-free, stromafree, medium containing SCF, FLT3, TPO and IL3 at final concentrations of 100 ng/ml, as previously described. 25 For the other three patients, Nos 3, 4 and 5, instead of using cultured CB cells, the strategy differed in the use of highly purified PB CD34
+ haploidentical cells obtained from a sibling by apheresis after 4 days of G-CSF given subcutaneously every 12 h. Purification was performed by positive/negative immunomagnetic selection using the Isolex 300i 2.0 Nexel (Irvine, CA, USA) system for patients Nos 3 and 4, and by positive selection using the Clini-MACS (Miltenyi-Biotec, Bergisch Gladbach, Germany) system for patient No. 5. Antibodies used in the negative selection step were anti-CD4 and anti-CD8 (Nexell) for patient No. 3, and these plus anti-CD3 (Ortho, Raritan, NJ, USA) for patient No. 
Pre-transplant conditioning
The regimen consisted of TBI, 12 cGy divided into six doses, given over 3 days with lung shielding at 800 cGy, cyclophosphamide 120 mg/kg, and ATG 75 mg/kg. CsA was initiated at −7 to −1 days and continued after the transplant at a dose adjusted to maintain the plasma level in the range of 180-200 ng/ml, unless a lower level was required because of toxic manifestations. Prednisone was given during the period of ATG treatment and after the transplant at a dose of 1 mg/kg until day +30 when it was discontinued unless required for treatment of manifestations of GVHD. Prior to transplantation, patients received a course of trimetoprin-sulphamethoxazol as prophylaxis for Pneumocistis carinii, and for herpes virus prophylaxis, gancyclovir from day −7 to −1 and acyclovir from day +1 to +28 were given. Patients were nursed in single rooms with filtered air at positive pressure and only foods of low microbiological content were provided. Prophylactic oral antibiotics (norfloxacin, ketokenazol and nystatin) were given, to be discontinued when intravenous antibiotic therapy was required for treatment of infections or fever. G-CSF was given from day +1 until engraftment.
Diagnostic methods
For pre-transplant HLA typing, serological methods were used for class I and molecular methods for class II loci, as these are methods used in CB banking. Trypan blue exclusion and/or 7-AAD flow cytometry were used to evaluate viability of the cellularity in the transplanted products. Analysis of DNA polymorphisms was used to identify the derivation of cells present in PB and BM samples after the transplant. In each case, this was carried out on the basis of the most appropriate microsatellite markers and of the HLA differentiating antigens using the RSCA method. 26 This method allows a relative quantification of the DNA from different possible origins (patient, purified CD34
+ cells, and unexpanded CB, as well as contaminating maternal cells in the CB units) with a sensitivity in the order of 3-5%. Table 2 shows histocompatibility, cell content and cell viability data for the transplanted products. Cell viability was 70-95% (median 84%). All CB units that were trans- Table 2 HLA compatibility and cell content data of transplanted products 
Results
Transplanted products
Engraftment
As may be seen in Table 3 , all five patients achieved haematopoietic reconstitution after the transplant. The two patients (Nos 1 and 2) who received cells of two CB units (uncultured and cultured) had sustained ANC Ͼ500/ml from, days +27 and +17 respectively. Patient No. 1 had a sustained platelet count of Ͼ20 000/ml without transfusion Table 3 Patients' post-transplant course 3 had a clearly biphasic recovery, with an initial wave of ANC Ͼ500/ml from days +12 to +16, reaching a maximum of 2040 on day +14. This was followed by lower counts from day +17 to day +26, and then by a long-lasting recovery. Patients Nos 4 and 5 had a continued ANC recovery, passing the 500/ml threshold on days +17 and +10, respectively.
Post-transplant chimerism
In the two patients who received cells from two CB units, DNA of the cultured cells was detected in BM and PB samples for a few days (1-3) around day +11, when the total leukocyte count was Ͻ200/l, but not in later samples. Thereafter, and from several days before the ANC increased to Ͼ500/l, the only donor DNA detected belonged to the uncultured CB units. Patient No. 1 reached full chimerism and patient No. 2 was in mixed (patient/uncultured CB) chimerism at the time of his death on day + 63 (Figures 1 and 2) .
In the three patients co-transplanted with CB and hap- loidentical CD34 + cells, DNA of this phenotype was detected, also transiently, in BM and PB samples starting on day +10 or +11. In patient No. 3 it was detected until day +17, coinciding with the first wave of granulocyte recovery, a cell population in which the haploidentical phenotype peaked at Ͼ90% of all DNA on day +14 (Figures 3, 4 and 5) . In patient No. 4 the haploidentical phenotype was detected until day +24 and was the predominant fraction in the DNA extracted from granulocytes on day +19, when ANC reached Ͼ500/l ( Figure 6 ). These two patients remained in full chimerism beyond day +24. In patient No. 5, haploidentical DNA was initially the predominant but then the declining fraction, while CB DNA was detected in increasing proportions from day +12 onwards, becoming the predominant fraction both in granulocytes and mononuclear cells at the time of death on day +56 (Figure 7 ). This patient had persistent marrow blasts, and traces of autologous DNA also were detected after the transplant.
In the two longest-surviving patients (Nos 1 and 3) there has been no reappearance of DNA belonging to the transplanted CD34 + cells (CB or haploidentical), which is consistent with no late development of lymphocytes from these cells.
Post-transplant clinical course
The patients did not have any major complications, infectious or otherwise, during the period of post-transplant neutropenia. Following engraftment, three patients had manifestations of acute GVHD that were only cutaneous: very mild and very quickly subsiding without specific treatment in patients Nos 1 and 5; grade I and promptly responding to steroid treatment in patient No. 3 (Table 3 ). Analysis of the DNA extracted from cutaneous biopsies of patients Nos 3 and 5 did not show evidence of infiltration by haploidentical cells. In all cases, this lack of major manifestations of acute GVHD allowed for rapid tapering of steroids and CsA in an attempt to minimize risks related to post-CB transplant immune deficiency, and to hasten possible GVT effects.
After engraftment and initial hospital discharge, the main clinical problems in four patients have been related to CMV, for which they received therapy with gancyclovir and/or foscarnet. Patients Nos 1 to 4 received pre-emptive courses upon detection of CMV antigenemia. The evolution has been favourable in patients Nos 1 and 3, whose survival at the time of writing is, respectively, more than 22 and 19 months; both remain in CR. In patients Nos 2, 4 and 5, rapidly evolving CMV infection resulted in death (+63, +71 and +56 days).
Bone Marrow Transplantation
Discussion
The relatively narrow HLA restriction that, compared to solid organ transplants, is required for BM or PB stem cell transplantation is related more to the risks inherent to the immune reaction of the transplanted cells against the host than to graft rejection. Thus, due to the relative naivety of its lymphoid cell content, the use of CB as a source of transplantable haematopoietic stem cells may reduce the need for a narrow HLA restriction. Indeed, available data suggest that CBTs result in a lower risk of severe GVHD and higher HLA disparity tolerance. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, CBT has problems related to risk of graft failure or relatively late engraftment, the median time of which is around 26 days, rarely occurring before day +20 in adult patients receiving Ͻ3.7 × 10 7 /kg nucleated cells. [1] [2] [3] [4] [5] [6] This late engraftment is most likely due to the relatively low number and early developmental stages of the haematopoietic progenitors present in the collected CB units. [27] [28] [29] [30] [31] In patients Nos 1 and 2, who received transplants of CB without post-thaw culture plus cells obtained by positive selection and ex vivo expansion culture of the CD34
+ cells from a HLA-different second CB unit, our results do not show contribution by the cultured cells to the recovery of circulating granulocytes. These reached the 500/l level after intervals (27 and 17 days) that are similar to what is usually observed in plain CBT both in children and adults, [1] [2] [3] [4] [5] [6] and DNA of the cultured cells was detected only in BM and PB sampled at earlier times (days +10 to +12). Similar results were observed in three other patients transplanted in another hospital using our protocol. 19 The lack of effectiveness of culture-expanded CB cells in producing a significant number of circulating granulocytes may reflect a lack of capacity for sustained proliferation. Alternatively, it could be a consequence of rejection, either by the residual immune system of the patient or by immune cells derived from the co-transplanted unmanipulated CB unit. The lack of contaminating lymphocytes in the cells of the cultured CB units might play a role in this regard. Although immune rejection could be a possibility, we believe it is unlikely, not only because of the intensive immune suppressive regimen the patients were receiving, but because of the disappearance of the cultured cell mark- The lack of adverse effects that could be related to the simultaneous transplantation of cultured cells allows the dual transplant model to be regarded as a potentially useful tool to evaluate the engraftment potential of CB cells grown in ex vivo expansion cultures in human recipients, as it has been recently described in a xenogeneic model. 21 This could allow progress in searching for culture conditions that could be more efficient than those we have used for our patients. Our data also suggest that the reported results of CB transplants in which an aliquot of the transplanted unit has been cultured prior to its delayed infusion should be interpreted with caution. [15] [16] [17] [18] Results obtained in the three patients (Nos 3, 4 and 5) who received the CB transplants together with the infusion of purified uncultured haploidentical CD34
+ cells highly depleted of contaminating lymphocytes suggest a promising alternative for reducing the risks inherent to the post-transplant period of neutropenia. Their different post-transplant dynamics, compared to cultured CD34 + CB cells, could be related to the larger number of infused cells or to a higher capacity for proliferation, as they are native and not precultured. Their otherwise limited capacity for lasting engraftment, reflected in the transient generation of granulocytes, may be related to the relatively low number of progenitors that we deliberately infused to keep the number of contaminating lymphocytes low. This may have resulted in a rapid exhaustion of the most primitive cells under highly proliferative stimuli, as grafts of a much larger number of lymphocyte-depleted HLA haploidentical CD34 + cells have been reported to result in long-lasting engraftment. 32 As previously discussed, the possibilities of immune rejection seems unlikely.
Simultaneous infusion of a limited number of haploidentical CD34
+ cells highly devoid of contaminating lymphocytes in conjunction with CB may be beneficial not only in reducing risks of bacterial and fungal infections, but also in allowing early initiation of prophylaxis or pre-emptive treatment for CMV with gancyclovir. Further study thus seems justified and desirable and this could benefit from a co-operative, multi-institutional approach. It can be speculated that the remarkably mild manifestations of GVHD observed in our patients might suggest that co-transplanted cultured CB cells or purified haploidentical PB CD34 + cells could affect the reactivity of the engrafted CB cells against the host.
In conclusion, we believe our data shows that: (1) the simultaneous infusion of uncultured CB cells and purified HLA mismatched haematopoietic progenitor cells has not resulted in unfavourable effects (prohibitive GVHD or CBT engraftment failure); (2) the double transplant model we have used is suitable for evaluating the engraftment potential of ex vivo cultured CB cells in the clinical setting; (3) the model may be an alternative strategy to improve engraftment of umbilical cord blood by co-infusion of either ex vivo expanded cells of a second umbilical CB unit or a limited number of uncultured sibling haploidentical cells; and (4) the culture conditions we used to expand CB cells have not resulted in early recovery of ANC.
It can be theorized that the double transplant approach could be combined with methods of pre-transplant coculturing in order to induce selective immunotolerance of the CB cells to the recipient antigens. 33 This might allow us to reduce the intensity of immunosuppressive regimens, thus reducing risks of opportunistic infections or even tumour relapse, since the possible anti-tumour immunotherapeutic effect of CBT might be enhanced.
